Additional GLP-1 receptor agonist approved for weight management
Since this module was created, the USA’s Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.
GLP-1 receptor agonists (GLP-1RAs) do more than simply lower blood glucose. This course takes a closer look at their potential role in tackling the rising tide of obesity, and with it two complications of obesity that present significant risk to the health of people with type 2 diabetes: non-alcohol related fatty liver disease (NAFLD) and non-alcohol related steatohepatatis (NASH).
By the end of this module, you will be able to:
✓ Explain obesity’s complex, multifactorial nature and the associated co-morbidities, complications and increased mortality in people with type 2 diabetes
✓ Outline the characteristics and progression of non-alcoholic fatty liver disease (NAFLD) and the increased risk for people with type 2 diabetes, hypertension and other co-morbidities of diabetes
✓ Explain the potential clinical use of glucagon-like peptide-1 receptor agonists in treating obesity and obesity-related complications for people with diabetes
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.